Elanco launches Befrena for canine allergic dermatitis treatment
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/13/2026
- Wall St futures decline as US-Iran escalation rattles sentiment
- SK Hynix’s record plunge drags down global chip stocks
- Oil gains over 3% as fresh military strikes threaten Hormuz shipments
- Ditching streaming could boost Disney stock by 40%, Wells Fargo says
- The real reason Meta shares are surging has nothing to do with its new AI model
Elanco Launches Befrena™ (tirnovetmab), New Anti-IL-31 Monoclonal Antibody, a Breakthrough Addition to the $1.3 Billion U.S. Canine Dermatology Market
May 18, 2026 7:27 AM EDTPhased launch of new anti-IL-31 monoclonal antibody is now underway, with product being used by select Early Experience Program veterinarians in clinics today
Befrena is effective for the treatment of dogs against allergic dermatitis and canine atopic dermatitis with no age or weight restrictions, and lasts 6 to 8 weeks, compared to the 4 to 8 weeks of the current market incumbent, lokivetmabStarts controlling itch within 24 hours and is given as an in-clinic injectionSelect Early Experience Program veterinarians are already using Befrena in clinical practice and seeing positive outcomesMeet Beaux,... More